about
Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paperThe role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinionEffects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studiesPreoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion.Ventriculoarterial decoupling in human septic shock.International evidence-based recommendations for focused cardiac ultrasound.Jugular vein distensibility predicts fluid responsiveness in septic patientsDesflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials.Remifentanil in critically ill cardiac patients.Unusual applications of noninvasive ventilation.Perioperative use of levosimendan: best practice in operative settings.Randomized evidence for reduction of perioperative mortality.Complications of non-invasive ventilation techniques: a comprehensive qualitative review of randomized trials.Reducing mortality in acute kidney injury patients: systematic review and international web-based survey.Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial.Volatile compared with total intravenous anaesthesia in patients undergoing high-risk cardiac surgery: a randomized multicentre study.Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.The Anesthetic Management of Transcatheter Aortic Valve Implantation.Sepsis After Cardiac Surgery: From Pathophysiology to Management.Worldwide Opinion on Multicenter Randomized Interventions Showing Mortality Reduction in Critically Ill Patients: A Democracy-Based Medicine Approach.A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): Rationale and design.Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study.Mixed reality for robotic treatment of a splenic artery aneurysm.Balloon aortic valvuloplasty before noncardiac surgery in severe aortic stenosis: a single-center experience.Mortality in Multicenter Critical Care Trials: An Analysis of Interventions With a Significant Effect.Anaesthetic management of transcatheter aortic valve implantation: results from the Italian CoreValve registry.Surgical treatment for life-threatening acute myocardial infarction: a prospective protocol.The easier, the better: age, creatinine, ejection fraction score for operative mortality risk stratification in a series of 29,659 patients undergoing elective cardiac surgery.Rebuttal: Transcatheter valve in ring procedures may be safety and feasibility procedures in carefully selected patients.Left ventricular reverse remodeling in percutaneous and surgical aortic bioprostheses: an echocardiographic study.Validation of a decision-making strategy for systolic anterior motion following mitral valve repair.Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization.Beta-adrenergic antagonists improve oxygen saturation in acute pulmonary edema: a case series in the prehospital setting.Reply to Carev et al: "Useful supplement to the best practice of using levosimendan in cardiac surgery patients: 2.5 mg intravenous bolus for cardiopulmonary resuscitation during perioperative cardiac arrest".Dysfunction of a 21-mm aortic bioprosthesis treated with percutaneous implantation of a CoreValve prosthesis.Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery.MortalitY in caRdIAc surgery (MYRIAD): A randomizeD controlled trial of volatile anesthetics. Rationale and design.Short-term effects of phenylephrine on systemic and regional hemodynamics in patients with septic shock: a crossover pilot study.The inodilator levosimendan as a treatment for acute heart failure in various settings.Sugammadex: hunting for new side effects?
P50
Q26738701-424DE1CF-0727-4CE0-91C4-594697FD856CQ26745542-A06F3740-952E-4AED-BAB8-430FF28B43FCQ28249459-74376EB4-59A6-45CB-B4F4-1A8621EE26CBQ30565685-DA4C496A-A59B-4DFC-A188-61CA45A31D7FQ33751885-DAEF7F33-5753-4E07-A2E0-C37064335E94Q34425897-37C2B98C-CC62-43CC-B5BD-80AD78D8B580Q34994398-B6A858C7-FCBE-4B22-895A-D84B04EB3992Q36902174-BB89C38A-01AF-4B5A-AD86-81035EB45CEDQ37825375-B88C27E8-7D01-410C-A573-B7D3762390A6Q37846994-E523FFE0-8C44-4D00-B31F-A19CF11A3378Q38015586-AD07BC98-F477-4594-9F41-8D3C6880A299Q38021061-4423B6FA-7549-41DA-926D-EC94FF9F413AQ38096755-1465B693-6DD6-48A7-B455-12ACC1F1D616Q38150584-8C614C4D-FF61-4BF5-953F-F0F460CB0AB5Q38423069-C1BEFA49-FDB4-4882-A75B-BEB4F55E0121Q38424227-B3E3A995-0B43-4741-95B6-4A3B7DBF9C71Q38443276-3CD6F152-5615-419E-8E7B-A843E17A7EC9Q38592444-E96E9EEE-FA16-4CF9-ADE7-CED521E54C33Q38762676-3DC43384-A8F3-4AA5-9AB7-5B32E81A1CB8Q38921289-AA01715F-AF10-4D8D-BAC8-8B4406B35A4AQ39685929-840D1540-E921-4A39-8624-D6D6FAF49C66Q39833414-ADFE7DA0-8F3E-493F-B333-7A8F74F162A4Q39938935-65650333-32A2-49D1-B887-A626584AAA22Q40905581-27E10D1C-222E-4829-90AE-110A97E380BAQ41141860-9C89798C-F13D-469C-A536-197039958B9FQ41218790-629E1980-3C78-4648-A165-F5369980F620Q42057160-D17F7BFB-3CB3-4244-A7D7-740E298E1790Q43555353-760CD580-A948-47C3-8494-94B557BDCFDEQ43765395-120D1660-8BA9-4792-8E86-BB6F495EC900Q43842697-0C344FC0-FEC4-4AD4-ABA9-A320821AF1CCQ43853524-8ADEA18B-15CD-4FEC-A1D9-83B43A536999Q44467781-84142FB2-D70C-4EB6-A6FA-D999E0A4E8CFQ44604129-6903802D-BFAF-4777-8994-321D78C597EBQ45743554-DEF1B817-CC99-4D81-A493-B499BB5DF199Q45785781-EC9A85DE-9B57-45C0-B404-C3B481B5DDEFQ46158758-0241600D-F599-4FAC-8A24-8E37E63A452EQ46634328-42C12768-E64C-4E63-801B-50A60EB79030Q46988846-5A887883-7C61-4E79-8DD5-36A70DFA4E93Q47097922-BFF9E547-77EB-40FB-97DF-5A4D155E92D3Q47228643-22EA237D-946E-4D10-A265-37E14051D69C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fabio Guarracino
@ast
Fabio Guarracino
@en
Fabio Guarracino
@es
Fabio Guarracino
@nl
Fabio Guarracino
@sl
type
label
Fabio Guarracino
@ast
Fabio Guarracino
@en
Fabio Guarracino
@es
Fabio Guarracino
@nl
Fabio Guarracino
@sl
prefLabel
Fabio Guarracino
@ast
Fabio Guarracino
@en
Fabio Guarracino
@es
Fabio Guarracino
@nl
Fabio Guarracino
@sl
P106
P1153
55411547300
P21
P31
P496
0000-0002-2562-0199